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Background: Assessment and appraisal of new medical technologies require a balance
between the interests of different stakeholders. Final decision should take into account
the societal value of new therapies.
Objective: This perspective paper discusses the socio-economic burden of disease as
a specific reimbursement decision-making criterion and calls for the inclusion of it as a
counterbalance to the cost-effectiveness and budget impact criteria.
Results/Conclusions: Socio-economic burden is a decision-making criterion,
accounting for diseases, for which the assessed medical technology is indicated. This
indicator is usually researched through cost-of-illness studies that systematically quantify
the socio-economic burden of diseases on the individual and on the society. This is a
very important consideration as it illustrates direct budgetary consequences of diseases
in the health system and indirect costs associated with patient or carer productivity
losses. By measuring and comparing the socio-economic burden of different diseases
to society, health authorities and payers could benefit in optimizing priority setting and
resource allocation. New medical technologies, especially innovative therapies, present
an excellent case study for the inclusion of socio-economic burden in reimbursement
decision-making. Assessment and appraisal have been greatly concentrated so far on
cost-effectiveness and budget impact, marginalizing all other considerations. In this
context, data on disease burden and inclusion of explicit criterion of socio-economic
burden in reimbursement decision-making may be highly beneficial. Realizing the
magnitude of the lost socio-economic contribution resulting from diseases in question
could be a reasonable way for policy makers to accept a higher valuation of innovative
therapies.
Keywords: health technology assessment, reimbursement, decision-making, cost-effectiveness, burden of
disease, socio-economic burden, cost-of-illness, rare diseases
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INTRODUCTION
The balance between the value of a health technology and
the effective access to it represents an important issue of
today’s health policy. Assessment and appraisal of new medical
technologies is a debate of political priorities, health system
specifics and societal expectations. In all countries, choices in
the allocation of resources are necessary. Health technology
assessment (HTA) has been introduced as a concept to address
rising health care costs and growing fiscal concerns (Iskrov and
Stefanov, 2016). Health economic data play a crucial role in
this process and the subsequent reimbursement decision-making
(Jakovljevic and Getzen, 2016).
Health technology assessment systematically explores the
properties and effects of a health technology, evaluating direct,
and intended effects, as well as indirect and unintended
consequences. These factors include safety, efficacy, effectiveness,
cost, cost-effectiveness, as well as expected social, legal, ethical,
and political impacts. There is a growing consensus on the
importance of balancing all these criteria, which are determining
the impact of a health technology on the healthcare system. In
this context, the progress in medical research and development
requires innovation of HTA process too. HTA should be updated
in order to respond to such challenges, as innovative health
technologies pose new critical factors, which affect patients,
payers and providers (Panzitta et al., 2015).
OBJECTIVE
This perspective paper discusses the socio-economic burden of
disease as a specific reimbursement decision-making criterion
and calls for the inclusion of it as a counterbalance to the cost-
effectiveness and budget impact criteria. The current limitations
of the latter in HTA of innovative therapies are outlined. We focus
on addressing these concerns through cost-of-illness studies.
This is illustrated through rare diseases and orphan drugs as a
paradigm of innovative health technologies.
COST-EFFECTIVENESS IN
REIMBURSEMENT DECISION-MAKING
Cost-effectiveness is a leading consideration in priority setting
and resource allocation. It is a utilitarianism-inspired idea,
aiming to achieve the biggest possible benefits to the widest range
of users. Its rationale is clear, as growing number of innovative
health technologies are available while budget resources are
limited. Cost-effectiveness is usually denoted as an incremental
cost-effectiveness ratio (ICER). ICER is defined as the ratio of the
change in costs of a therapeutic intervention (compared to the
alternative) to the change in effects of the intervention (Eichler
et al., 2004). In other words, it is the ratio of the extra costs to
the extra effects. Meeting this criterion is the most important
objective from health economic perspective. In practice, however,
few innovative health technologies tend to be cost-effective.
Appraisal is very often a choice between more costs and more
effects or less costs and less effects.
Incremental cost-effectiveness ratio is not a new concept.
Despite political will and public demand for transparent and
objective reimbursement decisions on new medical technologies,
there are very few examples of officially accepted and applied
ICER thresholds. UK’s National Institute for Health and Care
Excellence (NICE) is often mentioned as using, albeit implicitly,
ICER thresholds. Nevertheless, this institution has repeatedly
denied such statements. ICER does offer a range of theoretical
advantages, including reduced burden on decision-makers,
consistency and effectiveness of reimbursement decisions
(Eichler et al., 2004). However, this criterion remains a politically
and morally dividing issue. The implementation of an explicit
ICER threshold requires various comparisons and rankings
under strictly defined settings, which do not always exist in real
world. Moreover, there is no constant, context-independent
willingness to pay for each gained unit of health effect (McCabe
et al., 2008). Payers and society as a whole tend to give different
priority to different health technologies. In many occasions, there
is a need for flexibility and inclusion of ad hoc considerations
in these decisions. Furthermore, the single universal focus
on ICER as a reimbursement decision-making benchmark
is detrimental. ICER has been criticized for limiting patient
choice and health care rationing (Schnipper et al., 2015).
Finally, any positive ICER, no matter how appealing, represents
additional spending which may not be always affordable or
sustainable.
BUDGET IMPACT IN REIMBURSEMENT
DECISION-MAKING
The overall reimbursement decision on a new medical technology
requires a budget impact analysis. Opportunity costs are the main
reason for implementing this criterion. While various economic
analyses allow decision makers to assess the effectiveness of
health technologies, budget impact analysis is measuring the
financial impact of the adoption and use of a new medical
technology within the health system. Given the increasingly
stringent budgetary frameworks, regulators and payers demand
information on the impact that a new technology would have
on their limited budget (Niezen et al., 2009). In other words,
this indicator represents an assessment of the accessibility of a
new medical technology. Economic analyses provide the basis for
a favorable reimbursement decision and budget impact analysis
ultimately determines what resources would be needed to actually
implement this decision.
It is not surprising that budget impact considerations are
sometimes blamed for undermining the rational application
of the cost-effectiveness criterion (Niezen et al., 2009). Budget
impact is a substantial issue because health authorities attach
great importance to the sustainability of the health care system.
With regard to new medical technologies, they fear that the
costs of these innovative therapies would be significant and may
cause changes in resource allocation. In fact, studies showed
that health technologies with a high budget impact are much
more likely to be rejected for reimbursement or to be subject
of access restrictions than technologies with a limited impact
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(Mauskopf et al., 2013a,b). Furthermore, budget impact analysis
is posing some practical challenges for new medical technologies.
Especially in the case of highly innovative therapies, data
on the size of patient population, secondary costs, degree of
market penetration are difficult to estimate. Use of health care
information is traditionally fragmented and this is additionally
exacerbating the problem. Health care costs are usually divided
into several different budgets. Reimbursement decisions are often
taken at product level, without considering the spillover effect.
For example, an innovative drug may significantly increase the
costs for treatment, but at the same time it could also reduce the
costs for other health and social services (Iskrov and Stefanov,
2014).
EXTENSION OF THE SCOPE AND USE
OF HEALTH ECONOMIC DATA IN
REIMBURSEMENT DECISION-MAKING
Health economic data and their use could significantly affect
subsequent reimbursement decisions (Jakovljevic and Getzen,
2016). It is important that all relevant costs and outcomes of
the medical technology in question are identified and measured.
Direct and indirect costs should be included. The same goes for
positive and negative outcomes. Added societal value must be
considered as well. The choice of comparator is crucial and has
to be guided only by the evidence-based medicine. When a new
medical technology belongs to a well known therapeutic class,
this comparison is easily done. Nevertheless, many innovative
therapies represent a new therapeutic class themselves. In this
case, there is an additional risk for bias in the comparison (Iskrov
and Stefanov, 2014).
Reimbursement decision-making is not only about cost-
effectiveness and budget impact (Figure 1). Assessment and
appraisal of new medical technologies require a balance between
the interests of different stakeholders. Final decision should take
into account the societal value of new therapies. HTA itself does
not determine whether a new medical technology worth spending
of public funds for its use. This decision is ultimately taken by
health authorities and payers, who base their recommendations
on a combination of other criteria as well, including political
factors (Iskrov and Stefanov, 2016). Reimbursement decision-
making is always a question of trade-off. In the case of new
medical technologies, this issue is even controversial, as it consists
of two opposing principles – beneficence and justice. This is why
the role of health economic data in reimbursement decision-
making should further expanded. A clearly defined and accepted
use of socio-economic burden as a reimbursement criterion
could counterbalance the domination of the cost-effectiveness
and budget impact criteria.
FIGURE 1 | Socio-economic burden as a decision-making criterion in health technology assessment and appraisal.
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SOCIO-ECONOMIC BURDEN
Socio-economic burden is a decision-making criterion,
accounting for diseases, for which the assessed medical
technology is indicated (Figure 1). This measure is usually
researched through cost-of-illness studies that systematically
quantify the socio-economic burden of diseases on the individual
and on the society. This is a very important decision-making
consideration as it illustrates direct budgetary consequences of
diseases in the health system and indirect costs associated with
patient or carer productivity losses (Angelis et al., 2015b). While
cost-effectiveness and budget impact are describing the health
technology and its application, the socio-economic burden is
characterizing the disorder. It is a crucial point in terms of unmet
health needs and health inequalities. Accurate knowledge about
socio-economic burden is essential to formulate and prioritize
health care policies and technologies, as well as to allocate health
care resources in accordance with budget constraints in order to
achieve health policy efficiency (Jo, 2014).
There is no uniform definition for the burden of disease. High
socio-economic burden of disease does not necessarily mean
acute condition or frequent hospitalization. This indicator and
its values are more related to the degree, by which physical
and social symptoms affect the ability of patients to lead a
normal life and perform daily activities. It incorporates a high
dependence on family, relatives and carers, as well as frequent
follow-up by expert medical professionals. Despite being health
economic by nature, it is very important to engage clinicians
when defining this criterion and its scope (Jakovljevic et al., 2016).
Knowledge on disease epidemiology, morbidity and prognosis
is crucial. To understand socio-economic burden and to use it
efficiently in reimbursement decision-making, it is important
to analyze how socio-economic costs are defined, classified and
measured. Traditional paradigm of cost-of-illness studies puts
costs into three categories: direct, indirect and intangible costs.
Nevertheless, the decision-making focus is greatly on the first two
groups, as intangible costs are difficult to quantify. Furthermore,
the criterion of socio-economic burden of disease represents
the potential benefits of a new medical technology if it had
eradicated the disease. This type of health economic research is
closely related with the concept of disability-adjusted life years,
which encompass health care costs, as well as lost socio-economic
contribution resulting from premature death or disability (Jo,
2014).
SOCIO-ECONOMIC BURDEN OF
DISEASES AND HEALTH TECHNOLOGY
ASSESSMENT
New medical technologies, especially innovative therapies,
present an excellent case study for the inclusion of socio-
economic burden in HTA and reimbursement decision-making.
Innovative therapies are usually seen as recently introduced
or modified health technologies with unproven effect or side
effect undertaken in the best interest of the patient. They could
be anything from an innovation with no precedent to using
a conventional treatment in a different context. Assessment
and appraisal of these therapies tend to be one of the most
complicated tasks for health authorities and payers. It has been
acknowledged that, while regulatory incentives have stimulated
research and development of innovative therapies on a global
level, equitable and timely access to market approved ones
remains an issue. HTA has been heavily promoted a health
policy tool to ensure sustainability and credibility of the
reimbursement decision-making process. Despite best efforts,
there are legitimate concerns among medical professionals,
patients and industry that access to innovative therapies is greatly
delayed (Iskrov and Stefanov, 2014). It should not be forgotten
that HTA is only an instrument. Assessment and appraisal of
new medical technologies have been greatly concentrated so far
on cost-effectiveness and budget impact, marginalizing all other
considerations. It is important to underline that reimbursement-
decision making is perceived as fair and legitimate, when this
process leads to a balance and agreement among different
stakeholders’ interests. Reimbursement policy must recognize
public health priorities and fiscal constraints, but it should also
respect the individual health care right of each patient (Iskrov and
Stefanov, 2016).
These assumptions are particularly strong in the field of rare
diseases and orphan drugs. Rare diseases pose a unique challenge
to health authorities and payers, as they represent life-threatening
or chronically debilitating conditions with a low prevalence and
a high level of complexity. It is estimated that between 5 000 and
8 000 distinct rare diseases exist today, affecting between 6 and
8% of the population in the course of their lives. In other words,
the total number of people affected by rare diseases in the EU
is between 27 and 36 million. Because of their low prevalence,
their specificity and the high total number of people affected, rare
diseases call for a global approach based on special and combined
efforts to prevent significant morbidity or avoidable premature
mortality and to improve the quality of life and socio-economic
potential of affected persons (European Union, 2009).
Methods for health economic evaluation have their own
specifics when it comes to rare disease-related orphan medicinal
products. Orphan drugs are unable to meet the standard ICER
threshold. Moreover, health authorities and payers have strong
concerns about the increasing budget impact of those therapies.
These two considerations have historically had a negative impact
on the assessment and appraisal of orphan drugs (Rosenberg-
Yunger et al., 2011; Iskrov and Stefanov, 2014). In this context,
data on rare disease burden and inclusion of explicit criterion of
socio-economic burden in reimbursement decision-making may
be highly beneficial. Realizing the magnitude of the lost socio-
economic contribution resulting from rare disease premature
death or disability could be a reasonable way for policy makers
to accept a higher valuation of innovative therapies. Generation
of such evidence is crucial for the timely access to these
products.
The EU-funded BURQOL-RD project (Social Economic
Burden and Health-Related Quality of Life in Patients with
Rare Diseases in Europe) should be highlighted as the very
successful first step toward this objective. BURQOL-RD studied
both direct and indirect costs for 10 rare diseases in 8 EU
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Member States. While there were important differences between
countries depending on the degree of development of formal care
provided by social services, informal care was found to be the
main social resource involved in the care of people with rare
diseases (López-Bastida et al., 2016). Results from this project
showed the importance of studying the economic consequences
of rare diseases from a societal perspective and interpreting
the outcomes in a global framework. Burden of disease data
from BURQOL-RD provided insights into the distribution of
rare disease costs and their impact on national health system
expenditure, as well as on patient and family income (Angelis
et al., 2015a; López-Bastida et al., 2016). More importantly,
this study demonstrated that while direct costs for rare diseases
were significant, other indirect societal costs, such as informal
care, productivity loss and early retirement, were even higher.
In short, rare diseases represent considerable invisible costs to
the society and this should be taken into account when making
a reimbursement decision about orphan drugs and innovative
therapies for rare diseases.
CONCLUSION
Assessment and appraisal of new medical technologies is
a debate of political priorities, health system specifics and
societal expectations. Health economic data and their use
could significantly affect subsequent reimbursement decisions.
Reimbursement decision-making is not only about cost-
effectiveness and budget impact. Socio-economic burden
quantified through cost-of-illness studies is an important
and essential benchmark in health policy. By measuring and
comparing the socio-economic burden of different diseases to
society, health authorities and payers could benefit in optimizing
priority setting and resource allocation.
Generation of such evidence goes far beyond clinical trials and
requires multi-stakeholder cooperation and coordination. Early
constructive dialog and elaboration of disease-tailored research
tools could set the scene for ongoing accumulation of evidence,
as well as for proper and timely assessment and appraisal of new
medical technologies. Burden of disease data need to be updated
to understand the economics of diseases and their changing cost
structures. This will enable policymakers to better understand the
factors that impact on disease-related expenditure, and will also
enable a better-informed distribution of resources.
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